PatwardhanRVSchenkerS. Drug use in patients with liver disease—an overview. In: AndersonRJSchrierRW, eds. Clinical use of drugs in patients with kidney and liver disease. Philadelphia: WB Saunders, 1981: 166–81.
2.
MaxwellGECarellaMParkesJDWilliamsRMouldGPCurrySH. Plasma disappearance and clinical effects of chlorpromazine in cirrhosis. Clin Sci1972; 43: 143–51.
3.
ReadAELaidlawJMcCarthyCF. Effects of chlorpromazine in patients with hepatic disease. Br Med J1969; 2: 497–9.
4.
RobertsRKBranchRADesmondPVSchenkerS. The influence of liver disease on drug disposition. Clin Gastroenterol1979; 8: 105–21.
5.
RowlandMBlaschkeTFMeffinPJWilliamsRL. Pharmacokinetics in disease states modifying hepatic and metabolic function. In: BenetLZ, ed. The effect of disease states on drug pharmacokinetics. Washington, DC: American Pharmaceutical Association, 1976: 53–75.
6.
WilkinsonGRBranchRA. Effects of hepatic disease on clinical pharmacokinetics. In: BenetLZMassoudNGambertoglioJG, eds. Pharmacokinetic basis for drug treatment. New York: Raven Press, 1984: 49–61.
7.
GambertoglioJG. Effects of renal disease: Altered pharmacokinetics. In: BenetLZMassoudNGambertoglioJG, eds. Pharmacokinetic basis for drug treatment. New York: Raven Press, 1984: 149–71.
8.
FabreJBalantL. Renal failure, drug pharmacokinetics and drug action. In: GibaldiMPrescottL, eds. Handbook of clinical pharmacokinetics. Sidney: ADIS Press, 1983: (section III) 212–34.
9.
CurrySH. Chlorpromazine: Pharmacokinetics, plasma levels, and clinical response. In: BurrowsGDNormanTR, eds. Psychotropic drugs: Plasma concentration and clinical response. New York: Marcel Dekker, 1981: 243–86.
10.
MacKayAVPHealeyAFBaxterJ. The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics. Br J Clin Pharmacol1974; 1: 425–30.
